Topical therapies in inflammatory bowel disease.
Due to misunderstandings about their effectiveness and feasibility, topical (or rectal) therapies with aminosalicylates (5-aminosalicylic acid, 5-ASA) and steroids are often underused in patients with ulcerative colitis (UC). However, many of these patients could be treated solely with rectal/topical therapies, or could benefit from them in combination with oral therapies. We review the evidence for topical therapies containing 5-ASA and budesonide in UC and discuss how these therapies can be optimized in daily practice, thereby improving compliance. Finally, we provide a brief summary of studies on the use of other topical treatments in UC, the results of which were both promising and negative.
Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.
Pascal
P
Frei
Luc
L
Biedermann
Christine N
CN
Manser
Maike
M
Wilk
Michael
M
Manz
Stephan R
SR
Vavricka
Gerhard
G
Rogler
D000285:Administration, Rectal; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004733:Enema; D019983:Guideline Adherence; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D060046:Maintenance Chemotherapy / Q000379:methods; D019804:Mesalamine / Q000008:administration & dosage* / Q000627:therapeutic use; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D013488:Suppositories
D000893:Anti-Inflammatory Agents; D013488:Suppositories; D019804:Mesalamine; D019819:Budesonide